Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,502 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer(MONALEESA-2) | completed | Phase 3 | 668 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT00353496 | Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours(CLARINET) | completed | Phase 3 | 264 | IpsenINDUSTRY | 15 | Mar 5, 2025 |
| clinicaltrials |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | completed | Phase 3 | 623 | The Lymphoma Academic Research OrganisationOTHER | 7 | Mar 5, 2025 | clinicaltrials |
| NCT05865743 | Perioperative SDD to Prevent Infectious Complications After Esophagectomy(PERSuaDER) | recruiting | Phase 3 | 854 | Radboud University Medical CenterOTHER | 2 | Mar 5, 2025 | clinicaltrials |
| NCT01924819 | Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma(TOPGEAR) | active not recruiting | Phase 2 / Phase 3 | 574 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Mar 4, 2025 | clinicaltrials |
| NCT05297565 | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection(CheckMate-6GE) | completed | Phase 3 | 14 | Bristol-Myers SquibbINDUSTRY | 7 | Feb 27, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT01748448 | Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome(ViDMe) | completed | Phase 3 | 436 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Feb 17, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT02891824 | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab(ATALANTE) | completed | Phase 3 | 614 | ARCAGY/ GINECO GROUPOTHER | 7 | Feb 11, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases(CAIRO5) | completed | Phase 3 | 530 | Dutch Colorectal Cancer GroupOTHER | 2 | Feb 6, 2025 | clinicaltrials |
| NCT03692065 | API-CAT STUDY for APIxaban Cancer Associated Thrombosis(API-CAT) | completed | Phase 3 | 1,766 | Assistance Publique - Hôpitaux de ParisOTHER | 11 | Feb 6, 2025 | clinicaltrials |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated(ENHANCE-2) | terminated | Phase 3 | 258 | Gilead SciencesINDUSTRY | 15 | Feb 5, 2025 | clinicaltrials |
| NCT00887198 | Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,088 | Janssen Research & Development, LLCINDUSTRY | 11 | Feb 4, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Feb 4, 2025 | clinicaltrials |
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 10 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03796858 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy(COSMOS) | completed | Phase 3 | 285 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 14 | Feb 3, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT03366272 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients(NIVEAU) | completed | Phase 2 / Phase 3 | 348 | Universität des SaarlandesOTHER | 8 | Jan 28, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT02997202 | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 16 | Jan 17, 2025 | clinicaltrials |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | terminated | Phase 3 | 175 | Rain Oncology IncINDUSTRY | 15 | Jan 14, 2025 | clinicaltrials |
| NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer(VISION) | completed | Phase 3 | 861 | EndocyteINDUSTRY | 10 | Jan 13, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
| NCT05055648 | PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy(PROTECT) | recruiting | Phase 3 | 396 | University of AarhusOTHER | 8 | Dec 17, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT03553836 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | active not recruiting | Phase 3 | 976 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Nov 29, 2024 | clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | completed | Phase 3 | 656 | TakedaINDUSTRY | 33 | Nov 19, 2024 | clinicaltrials |
| NCT01740427 | A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) | completed | Phase 3 | 666 | PfizerINDUSTRY | 18 | Nov 14, 2024 | clinicaltrials |
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT04934475 | MInimal Residual Disease Adapted Strategy(MIDAS) | active not recruiting | Phase 3 | 791 | Intergroupe Francophone du MyelomeNETWORK | 3 | Nov 7, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials